Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.samratpharmachem.com | |
Market Cap | 103.03 Cr. | |
Enterprise Value(EV) | 122.69 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.07 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 205.85 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.62 | Calculated using Price: 333.45 |
Dividend Yield | 0.30 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.31 Cr. | 3,089,700 Shares |
FaceValue | 10 | |
About Samrat Pharmachem Ltd. | ||
Samrat Pharmachem was incorporated on June 16, 1992, at Ankleshwar in Gujarat. It was promoted by Lalit Mehta & Rajesh Mehta. The company is currently manufacturing iodine salts & bromine salts. The finished products produced by the company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc. The products of the company are well received in Indian & foreign markets. The company is a public limited company & its shares are listed & traded on the Bombay Stock Exchange & other bourses of India. The company is presently employing 30 people for its operations at Ankleshwar & Mumbai. |
1 Day |
|
-1.87% |
1 Week |
|
-3.66% |
1 Month |
|
-9.72% |
3 Month |
|
-4.62% |
6 Month |
|
-16.32% |
1 Year |
|
-9.25% |
2 Year |
|
-30.96% |
5 Year |
|
+438.69% |
10 Year |
|
+1567.25% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 2.38 | 2.21 | 12.07 | 19.01 | 7.96 | 19.1 | 19.77 | 44.95 | 30.25 | |
Return on Capital Employed (%) | 6.45 | 5.31 | 16.4 | 23.05 | 11.8 | 22.43 | 23.9 | 52.33 | 34.91 | |
Return on Assets (%) | 1.1 | 0.97 | 4.86 | 8.37 | 3.79 | 8.6 | 9.22 | 24.2 | 16.57 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 13 | 14 | 15 | 19 | 20 | 24 | 30 | 47 | 63 | 63 | |
Non Curr. Liab. | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | |
Curr. Liab. | 12 | 20 | 19 | 21 | 19 | 34 | 27 | 37 | 53 | 47 | |
Minority Int. | |||||||||||
Equity & Liab. | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 | 110 | |
Non Curr. Assets | 8 | 8 | 8 | 8 | 7 | 9 | 10 | 13 | 18 | 19 | |
Curr. Assets | 18 | 28 | 28 | 33 | 33 | 50 | 47 | 71 | 99 | 92 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 | 110 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 48 | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 311 | 268 | |
Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | |
Total Income | 49 | 63 | 73 | 93 | 112 | 138 | 179 | 222 | 311 | 269 | |
Total Expenditure | -47 | -62 | -69 | -87 | -108 | -131 | -170 | -198 | -287 | -267 | |
PBIDT | 2 | 1 | 4 | 6 | 4 | 7 | 9 | 25 | 24 | 2 | |
Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 | |
Taxation | 0 | 0 | -1 | -2 | -1 | -2 | -2 | -6 | -6 | 0 | |
Exceptional Items | 0 | 0 | 0 | ||||||||
PAT | 0 | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 0 | |
Adjusted EPS | 1 | 1 | 6 | 10 | 5 | 14 | 17 | 56 | 54 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 4 | -1 | 0 | -3 | 0 | 2 | -1 | 5 | 17 | -9 | |
Cash Fr. Inv. | 0 | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | -3 | |
Cash Fr. Finan. | -1 | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | 10 | |
Net Change | 2 | 0 | 0 | -1 | -1 | 1 | -1 | 0 | 14 | -3 | |
Cash & Cash Eqvt | 2 | 2 | 4 | 2 | 1 | 2 | 0 | 0 | 15 | 12 |
Thu, 28 Mar 2024
Closure of Trading Window The Trading Window of the company shall remain closed from Monday April 1 2024 till 48 hours after the declaration of Audited Financial Results for the year ended 31st March 2024 for all Designated persons including their immediate relatives. |
Thu, 28 Mar 2024
Board Meeting Intimation for Notice Of Board Meeting For Audited Financial Results For The Year Ended March 31 2024 SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve the Audited Standalone Financial Results of the company for the quarter and year ended March 31 2024.The Board of Directors may consider a proposal to recommend dividend on the equity shares of the company for the financial year ended March 31 2024. |
Tue, 05 Mar 2024
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot Postal Ballot Notice with Explanatory Statement |
Thu, 28 Mar 2024 |
High Delivery Percentage |
Making Lower Lows for 3 days |
Close Within 52 Week Low Zone |
Close Below Last Month Low |
Making Lower Lows for 2 Days |